Literature DB >> 6762370

Functional evaluation of Duchenne muscular dystrophy: proposal for a protocol.

F Cornelio, F Dworzak, L Morandi, E Fedrizzi, M R Balestrini, L Gondoni.   

Abstract

A protocol for the evaluation of functional activities in subjects with Duchenne muscular dystrophy (DMD) was designed. The aim of our study was to define objective clinical criteria for the evaluation both of the clinical status of the patient and of the natural history of the illness itself. A protocol with such criteria is particularly necessary when testing the efficacy of treatment. 43 still-ambulant children with DMD between the ages of 3.10 yr and 10.4 yr were examined. Of this number 19 children were evaluated every 4 months over a period of 12 months; of these 14 formed part of a randomized double blind trial with L-carnitine (1.2-1.8 g/day) versus placebo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6762370     DOI: 10.1007/bf02043581

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  16 in total

1.  Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases.

Authors:  C A SWINYARD; G G DEAVER; L GREENSPAN
Journal:  Arch Phys Med Rehabil       Date:  1957-09       Impact factor: 3.966

Review 2.  Roles of branched-chain amino acids in metabolic regulation.

Authors:  S A Adibi
Journal:  J Lab Clin Med       Date:  1980-04

3.  Oral treatment of carnitine myopathy.

Authors:  G P Hosking; N P Cavanagh; D P Smyth; J Wilson
Journal:  Lancet       Date:  1977-04-16       Impact factor: 79.321

4.  Clinical trial in Duchenne dystrophy. I. The design of the protocol.

Authors:  M H Brooke; R C Griggs; J R Mendell; G M Fenichel; J B Shumate; R J Pellegrino
Journal:  Muscle Nerve       Date:  1981 May-Jun       Impact factor: 3.217

5.  Glass capillary gas chromatographic determination of N tau-methylhistidine in urine.

Authors:  L Cotellessa; F Marcucci; D Cani; P Sfondrini; L Colombo; E Mussini
Journal:  J Chromatogr       Date:  1980-11-14

6.  The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features.

Authors:  G Karpati; S Carpenter; A G Engel; G Watters; J Allen; S Rothman; G Klassen; O A Mamer
Journal:  Neurology       Date:  1975-01       Impact factor: 9.910

7.  Psychometric studies in muscular dystrophy type 3a (Duchenne).

Authors:  H Zellweger; J W Hanson
Journal:  Dev Med Child Neurol       Date:  1967-10       Impact factor: 5.449

8.  Treatment of Duchenne's muscular dystrophy with penicillamine. Results of a double-blind trial.

Authors:  R I Roelofs; G S de Arango; P K Law; D Kinsman; D C Buchanan; J H Park
Journal:  Arch Neurol       Date:  1979-05

9.  Lack of benefit of allopurinol in Duchenne dystrophy.

Authors:  J R Mendell; D O Wiechers
Journal:  Muscle Nerve       Date:  1979 Jan-Feb       Impact factor: 3.217

10.  Evaluation and detection of Duchenne's and Becker's muscular dystrophy carriers by manual muscle testing.

Authors:  M S Roses; M T Nicholson; C S Kircher; A D Roses
Journal:  Neurology       Date:  1977-01       Impact factor: 9.910

View more
  5 in total

Review 1.  Genetic and clinical correlations of Xp21 muscular dystrophy.

Authors:  K M Bushby
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Pathomechanics of Gowers' sign: a video analysis of a spectrum of Gowers' maneuvers.

Authors:  Richard F Chang; Scott J Mubarak
Journal:  Clin Orthop Relat Res       Date:  2011-12-28       Impact factor: 4.176

3.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history.

Authors:  K M Bushby; D Gardner-Medwin
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

4.  Identification of a mutation in the promoter region of the dystrophin gene in a patient with atypical Becker muscular dystrophy.

Authors:  K M Bushby; N J Cleghorn; A Curtis; I D Haggerty; L V Nicholson; M A Johnson; J B Harris; S S Bhattacharya
Journal:  Hum Genet       Date:  1991-12       Impact factor: 4.132

5.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.